Sunitinib: all 340 studies that test it

Page 4 of 4. Open to participants first (13), then studies with results posted, then the rest; newest registration first within each.

• Bevacizumab in Multiple Phase I CombinationsCompletedNCT00543504Phase 1
• Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase InhibitorCompletedNCT00543049Phase 2
• Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell CancerCompletedNCT00541008Phase 2
• SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma MultiformeStatus unknownNCT00535379Phase 2
• A SU011248 Expanded Access Protocol for Systemic Therapy of Patients With Metastatic Renal Cell Carcinoma Who Are Ineligible for Participation in Other SU011248 Protocols But May Derive Benefit From Treatment With SU011248CompletedNCT00531544Not applicable
• A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid TumorsCompletedNCT00528619Phase 1
• Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCCTerminatedNCT00522249Phase 1/2
• Sunitinib Malate in Treating East African Patients With Kaposi SarcomaWithdrawnNCT00521092Phase 2
• Sunitinib in Treating Patients With Liver Cancer That Cannot Be Removed by SurgeryCompletedNCT00514228Phase 2
• Study Of SU011248 In Combination With Paclitaxel/Carboplatin In Patients With Advanced Solid TumorsCompletedNCT00511849Phase 1
• Thyroid Cancer and SunitinibCompletedNCT00510640Phase 2
• A Phase I/II Study of Sunitinib and DacarbazineTerminatedNCT00496223Phase 1/2
• Sunitinib in Treating Patients With Newly Diagnosed Stage II or Stage III Breast Cancer That Can Be Removed by SurgeryCompletedNCT00482755Phase 2
• A Study of Neoadjuvant Sutent for Patients With Renal Cell CarcinomaTerminatedNCT00480935Phase 2
• Sunitinib and Gemcitabine in Treating Patients With Pancreatic Cancer or Other Solid TumorsCompletedNCT00462553Phase 1
• Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell CarcinomaCompletedNCT00444314Phase 2
• Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer PatientsCompletedNCT00437372Phase 1
• Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung AdenocarcinomaCompletedNCT00430261Phase 2
• A Study of RAD001 and Sunitinib in Metastatic Renal Cell CarcinomaCompletedNCT00422344Phase 1
• A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma PatientsCompletedNCT00421512Phase 1
• Efficacy of SU 011248 in Head And Neck CarcinomaTerminatedNCT00408252Phase 2
• Study of Combination of Sirolimus and Sutent in Patients With Advanced Solid Tumors Non-Curable With Standard TherapyTerminatedNCT00402415Phase 1
• Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal CancerCompletedNCT00400114Phase 2
• Perifosine + Sunitinib Malate for Patients With Advanced CancersCompletedNCT00399152Phase 1
• Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With GemcitabineCompletedNCT00397787Phase 2
• Sunitinib in Treating Young Patients With Refractory Solid TumorsCompletedNCT00387920Phase 1
• Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the UterusCompletedNCT00378911Phase 2
• Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell CarcinomaCompletedNCT00372853Phase 1
• Phase-II Study of SU011248 (Sunitinib)in Male Patients With Relapsed or Cisplatin-Refractory Germ Cell CancerCompletedNCT00371553Phase 2
• SU011248 in Advanced Hepatocellular CarcinomaCompletedNCT00361309Phase 2
• SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal CancerTerminatedNCT00361244Phase 1/2
• Bevacizumab and Sunitinib in Treating Patients With Solid TumorsCompletedNCT00357318Phase 1
• Sunitinib Malate With Hormonal Ablation for Patients Who Will Have ProstatectomyActive, not recruitingNCT00329043Phase 2
• Temodar and Sutent as Therapy for MelanomaTerminatedNCT00304200Phase 1/2
• SU11248 as Consolidation After Response to Taxanes in Metastatic Breast CancerCompletedNCT00270413Phase 2
• Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast CancerCompletedNCT00174434Phase 1
• Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung CancerCompletedNCT00092001Phase 2
• A Study of SU11248 In Patients With Metastatic Breast Cancer Who Have Failed Selected Other Therapies.CompletedNCT00078000Phase 2
• Assessment Of Safety And Efficacy Of SU11248 In Patients With Metastatic Colorectal Cancer Who Have Failed Selected Previous Treatments.CompletedNCT00077987Phase 2
• Treatment With SU11248 in Patients With Neuroendocrine TumorsCompletedNCT00056693Phase 2

← Sunitinib overview